Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Kenneth K. Yu"'
Autor:
Kenneth K. Yu, MD, PhD, Lauren Franzblau, BS, Douglas R. Fullen, MD, Shannon A. Carty, MD, Trilokraj Tejasvi, MD, MBBS
Publikováno v:
JAAD Case Reports, Vol 4, Iss 4, Pp 314-317 (2018)
Externí odkaz:
https://doaj.org/article/e98a495e05aa4dc6871e9e687a43b06d
Autor:
Kenneth K. Yu, Neal P. Smith, Sernah V. Essien, Jessica E. Teague, Pablo Vieyra-Garcia, Ahmed Gehad, Qian Zhan, Jack D. Crouch, Nega Gerard, Cecilia Larocca, Peter Wolf, Nicole R. LeBoeuf, Marianne Tawa, Thomas S. Kupper, Alexandra-Chloé Villani, Rachael A. Clark
Publikováno v:
Journal of Investigative Dermatology. 142:2285-2288.e2
Autor:
Kenneth K. Yu, Johann E. Gudjonsson, Stephanie J.T. Chen, Alexander T. Reid, Rajiv M. Patel, Lori Lowe, Steven M. Donn
Publikováno v:
JAAD Case Reports, Vol 4, Iss 4, Pp 333-336 (2018)
JAAD Case Reports
JAAD Case Reports
Publikováno v:
JAAD Case Reports
JAAD Case Reports, Vol 4, Iss 4, Pp 314-317 (2018)
JAAD Case Reports, Vol 4, Iss 4, Pp 314-317 (2018)
Publikováno v:
JAAD Case Reports
Rosai–Dorfman disease (RDD) is a benign non–Langerhans cell histiocytosis with a predilection for the head and neck lymph nodes, although it may present extranodally in the skin, soft tissue, or the central nervous system. The diagnosis depends o
Autor:
Chrysalyne D. Schmults, Kenneth K. Yu, A. Piris, Y. Hirakawa, Qian Zhan, Nathalie Y. R. Agar, Walid M. Abdelmoula, S. Essien
Publikováno v:
Journal of Investigative Dermatology. 141:S116
Publikováno v:
Journal of Investigative Dermatology. 141:S118
Publikováno v:
J Am Acad Dermatol
BACKGROUND: Bullous pemphigoid (BP) responds to a variety of immunosuppressive agents and usually controls, but does not cure, the disease. Omalizumab, Food and Drug Administration—approved for asthma, selectively suppresses the activity of IgE, an
Autor:
Thomas S. Kupper, Kenneth K. Yu, Rachael A. Clark, Wiebke Pruessmann, Rachel N. Cotton, Jessica E. Teague, A. Gehad, D.B. Moody, A. Vromans, A. de Masson, J. Crouch
Publikováno v:
Journal of Investigative Dermatology. 139:S178
Autor:
Kenneth K, Yu, Constantin A, Dasanu
Publikováno v:
Connecticut medicine. 80(6)
Alemtuzumab is FDA-approved for the treatment of chronic lymphocytic leukemia (CLL). Nonetheless, its use for this indication has fallen out of favor due to serious concerns for infectious complications and increased risks of second malignancies from